Cutia Therapeutics, incorporated in the Cayman Islands with limited liability, released its monthly return for November 2025. The company’s authorized share capital remains unchanged at 2,500,000,000 ordinary shares with a par value of USD 0.00002 each, totaling USD 50,000.

During November 2025, the number of issued shares (excluding treasury shares) rose from 348,370,511 to 363,368,277, while treasury shares stayed at 1,362,600, bringing the total to 364,730,877. The 14,997,766-share increase resulted from the exercise of share options under the Pre-IPO Equity Incentive Plan.

According to the filing, 14,997,766 share options were exercised under the Pre-IPO Equity Incentive Plan, reducing the outstanding options under this plan from 52,197,774 to 37,200,008. The company reported that no funds were raised (USD 0) during this period from the exercise of these share options. The Post-IPO Equity Incentive Plan recorded no changes for the month.